Published in final edited form as:

Biochem Biophys Res Commun. 2013 May 3; 434(2): 263–267. doi:10.1016/j.bbrc.2013.02.114.

Cell penetrating recombinant Foxp3 protein enhances Treg function and ameliorates arthritis

Kentaro Yomogida¹, Shili Wu², Bobby Baravati², Camilo Avendano², Tom Caldwell², Brian Maniaci², Yong Zhu², and Cong-Qiu Chu¹

¹Oregon Health & Science University and Portland VA Medical Center, 3181 S.W. Sam Jackson Park Rd, OP09, Portland, Oregon 97239-3098

²VivoScript, Inc, 3505 Cadillac Ave., STE F7, Costa Mesa, CA 92626

Abstract

Foxp3 is the master transcription factor for T regulatory (Treg) cell differentiation and function. This study aimed to test the therapeutic potential of cell penetrating recombinant Foxp3 protein in arthritis. Recombinant Foxp3 protein was fused to a cell penetrating polyarginine (Foxp3-11R) tag to facilitate intracellular transduction. *In vitro* Foxp3-11R treated CD4⁺ T cells showed a 50% increase in suppressive function compared with control protein treated cells. Severity of arthritis in Foxp3-11R treated mice was significantly reduced compared with those treated with a control protein. CD4⁺ T cells of lymph nodes and spleen from Foxp3-11R treated mice showed increased levels of Foxp3 expression compared with those of a control protein treated. These results demonstrated that Foxp3-11R can enhance T cell suppressive function and ameliorate experimental arthritis and suggest that cell penetrating recombinant Foxp3 is a potentially useful agent in therapy of arthritis.

Keywords

Foxp3; T regulatory cells; Arthritis

1. Introduction

Immune homeostasis is mediated by a complex system of central and peripheral mechanisms. T regulatory (Treg) cells play a crucial role in maintenance of self-tolerance in periphery. Treg cells are a subset of CD4⁺ helper T cells and Foxp3 is the master transcription factor for Treg function [1]. The exact mechanisms how Foxp3 regulates Treg function is not fully elucidated yet, but it is considered to be achieved through its interaction with other transcription factors such as NFAT, NF- κ B and RORC, and regulation of multiple other genes [2]. Mutations in Foxp3 gene result in dysfunction of Treg cells and severe autoimmune inflammation [3]. Decreased number of and impaired function of Treg cells have been demonstrated in autoimmune disorders including systemic lupus erythematosus, rheumatoid arthritis (RA), multiple sclerosis and type 1 diabetes [4].

Corresponding author: Cong-Qiu Chu, MD, PhD, chuc@ohsu.edu.

Competing Interests

SW, BB, CA, TC, BM and YZ are employees of VivoScript, Inc.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Therefore, restoration of Treg cell function and administration of *in vitro* generated Treg cells are a potential therapeutic strategy to those autoimmune diseases [4]. Previous studies using Treg cells as therapy have focused on cell based treatment. Although some positive effects have been reported, cell based therapy have suffered from intrinsic disadvantages with requirement of long term *in vitro* expansion and maintenance of Treg cells. Injected Treg cells proved to be instable and have the potential to change phenotype and loss of regulatory function. Moreover, injected Treg cells may produce detrimental rather than therapeutic effects since Treg cells can transform *in vivo* to pathogenic Th17 or Th1 like effector cells [5,6,7]. To overcome the problems associated with cell based Treg cell therapy, a novel approach to promotion of Treg cell function *in vivo* has been attempted. Since induction of Foxp3 in naïve T cells converts naïve T cells into Treg-like cells [1,8], several studies have tried genetically induction and modification, or direct delivery of Foxp3 for clinical use [9,10,11]. However, the application is still limited due to its potential risk of delivery method or lower transfection efficiency.

Several short peptides, such as HIV tat and polyarginine, can cross cellular membrane. Previous reports have demonstrated stable delivery of recombinant proteins into cells using these short peptides [12,13]. In order to facilitate Foxp3 protein delivery, we created recombinant Foxp3 protein fused with polyarginine (11R). In this report, we demonstrated that Foxp3-11R converted mouse T cells into Foxp3^{high} Treg-like cells and these Treg-like cells suppress other T cell proliferation *in vitro*. Additionally, systemic administration of Foxp3-11R alleviated arthritis of SKG mice. These results propose a stable delivery method of Foxp3 proteins into T cells and its potential use for therapy of autoimmune diseases.

2. Materials and methods

2.1. Gene construction and protein production of recombinant Foxp3-11R and ASCL1-11R

Our target protein construct is a human Foxp3 protein (NP_054728.2) fused with a C-terminal polyarginine tag (11R) via a linker (ESGGGGSPG). The cDNA sequence of this construct was first optimized for high level protein expression in *E. coli* and then synthesized by GenScript (Piscataway, NJ). Next, the gene was sub-cloned into vector pET-15b via NdeI and BamHI restriction enzyme sites. As a result, the expressed protein also has an N-terminal polyhistidine (6H) tag (Figure 1A). The gene of ASCL1-11R was designed and constructed in the same way. The above protein expression plasmids were transformed into BL21 (DE3) competent cells, and protein production, refolding, and purification were carried out with procedures as previously described [13].

2.2. Flow cytometry

The mAbs used for flow cytometric analysis were: FITC- or APC anti-CD3 (2C11; BD bioscience), FITC- or PE-anti-CD4 (G.K1.5; BioLegend), PE-anti-CD25 (3C7; BD Bioscience), APC-Foxp3 (FJK16s; eBioscience). For analysis of Foxp3 transduction, cells were fixed and permeabilized using Fixation/Permeabilization buffer (eBioscience) followed by incubation with the specific Abs. FITC-Annexin V (BioLegend) staining was performed by following a standard protocol as described [14].

2.3. Foxp3-11R transduction assay

SKG mouse splenocytes were cultured with 10 µg/ml of Foxp3-11R or ASCL1-11R in anti-CD3/28 mAb (Bioxcel) pre-coated round bottomed 96-well plate for 48 hours. After incubation, intracellular Foxp3 and CD25 on cell surface were stained.

2.4. Treg-like cell suppression assay

As suppressor cells, SKG mouse splenocytes were incubated with 10 µg/ml of Foxp3-11R or ASCL1-11R for 1 hour and washed twice with culture medium. As responder cells, SKG mouse splenocytes were stained with 1 µg/ml of CFSE for 10 minutes, and washed twice with warmed PBS and culture medium. After creating suppressor and responder cells, both cells were cultured at various ratio (sup:res = 1:2, 5:1) and were stimulated with anti-CD3/CD28 coated 96 well plate for 72 hours. Cell proliferation of responder cells were measured by flow cytometry.

2.5. SKG mice, arthritis induction and disease monitoring

Arthritis was induced by intraperitoneal injection of 2 mg of zymosan in 6 weeks old female SKG mice. The day of zymosan injection was defined as day 1. From day 8 to day 14, 40 µg of Foxp3-11R or ASCL1-11R were injected intraperitoneally and severity of arthritis was graded. Joint swelling was monitored by inspection and scored as follows: 0, no joint swelling; 0.1, mild swelling of one finger joint; 0.2, severe swelling of one finger joint; 0.5, mild swelling of wrist or ankle; 1.0, moderate swelling of write or ankle; 1.5, severe swelling of wrist or ankle. Scores for all fingers of fore paws and hind paws, wrists and ankles were summed for each mouse. The maximum of score for each mouse is 9.6. The study was approved by the Institutional Animal Care and Use Committee of Portland VA Medical Center.

2.6. Statistics

Two-tailed student *t* test and Mann-Whitney U test were performed for statistical analysis.

3. Results and Discussion

3.1. Foxp3-11R penetrate cell membrane

To create cell-penetrating Foxp3 protein, we designed and fused a polyarginine (i.e. 11R) protein transduction domain to the C-terminus of the human Foxp3 protein (Figure 1A). We also added a polyhistidine (6H) tag to the N-terminus for purification and detection. The protein was expressed in *E. coli* in inclusion body form, which was then solubilized, refolded, and further purified. The protein identity was confirmed by SDS-PAGE and Western blot analysis. Similarly, we constructed and prepared the ASCL1-11R protein as a control protein. To examine the transduction efficiency, splenocytes from SKG mouse were incubated with Foxp3-11R or irrelevant control protein ASCL1-11R, and intracellular Foxp3 level was assessed. Higher levels of Foxp3 were detected in Foxp3-11R treated group compared to control groups, and this confirmed transduction of Foxp3-11R (Figure 1 B). Since polyarginine is cell membrane permeant cationic and potentially cytotoxic, we assessed the viability of the spleen cells by Annexin V staining after exposure to Foxp3-11R or ASCL1-11R. As shown in Figure 1 C, there is no significant increase in Annexin V positive cells in either Foxp3-11R or ASCL1-11R treated spleen cells as compared with those cultured in medium alone. These data indicate that polyarginine tagged Foxp3 (Foxp3-11R) is not toxic to the cells and is potentially safe to be administered *in vivo* as a therapeutic agent.

3.2. Foxp3-11R converted T cells to Treg-like cells

Next, we investigated T cell suppressive function of Foxp3-11R. Treg cells were initially characterized as CD4⁺CD25^{high} T cells with immunosuppressive function [15]. We examined CD25 expression after Foxp3-11R treatment. Surprisingly, CD25 was not altered by Foxp3-11R treatment (Figure 2A). In order to assess its role in T cells, we performed Treg-like cell suppression assay. In this assay, suppressor cells were prepared by Foxp3-11R

treatment, and responder cells were stained with CFSE. Subsequently, suppressor cells and responder cells were mixed at various ratios and function of Treg-like cell was evaluated by proliferation of responder cells. Foxp3-11R treated T cells significantly inhibited proliferation of responder cells (Figure 2B). This indicated that Foxp3-11R treated T cells gained suppressive function and may have been converted to Treg-like cells.

3.3. Foxp3-11R ameliorated arthritis in SKG mice

We next investigated the clinical application of Foxp3-11R in arthritis model. SKG mice have a mutation in gene encoding ZAP-70 along with a defective Treg function and develop chronic arthritis which most closely resembles human rheumatoid arthritis [16]. The impaired Treg cell function might be a contribution factor for SKG mice developing arthritis. Therefore, SKG mouse arthritis serves as a right model to test the capacity of Foxp3-11R in treating arthritis. First, we assessed *in vivo* delivery of Foxp3-11R. Seven days after induction of arthritis by zymosan, Foxp3-11R or ASCL1-11R was given systemically for 7 days. Fourteen days after final treatment, lymph nodes and splenocytes were harvested and intracellular Foxp3 level was measured. As shown in Figure 3A, increased level of Foxp3 was detected from Foxp3-11R treated group and this indicated that Foxp3-11R was delivered intracellularly even by systemic injection.

Development of clinical arthritis in SKG mice became visible around 2 weeks after zymosan injection. Mice in ASCL1-11R treated group develop more severe arthritis and the disease progressed (Figure 3B). In contrast, mice in Foxp3-11R treated group had significantly reduced severity of arthritis. This effect lasted for 7 weeks. These results showed that Foxp3-11R treatment ameliorated arthritis in SKG mice.

Impaired Treg function is associated with multiple autoimmune diseases. Intensive research has been focused on therapeutic interventions to enhance Treg cell numbers and Treg cell function in autoimmune diseases [17]. Those approaches include *ex vivo* expansion of Treg by cytokines and viral mediated Foxp3 transfection [9,18,19,20]. However, stability of Treg cells created *ex vivo* is still questionable and viral mediated transfection has concern in its safety for human application. Moreover, *in vitro* generated Treg cells can potentially differentiate into effector cells *in vivo* [5,6,7]. In this report, we demonstrated that recombinant Foxp3-11R was delivered into cells stably both *in vitro* and *in vivo* and converted T cells to Treg-like cells which inhibited proliferation of responder T cells and ameliorated arthritis.

It is interesting that Foxp3-11R treatment enhanced Treg cell function both *in vitro* and *in vivo* by enhancing Foxp3 expression but did not seem to affect expression of CD25. CD25 is the α -chain of high affinity IL-2R complex. IL-2R receptor signaling is critical for functional maturation of natural Treg cells during thymic development [21] and consumption of IL-2 by means of high CD25 expression is considered to be an important mechanism in maintaining Foxp3 expression in periphery [22]. Indeed, CD25 deficient mice have poorly functional Treg due to lower Foxp3 [23]. All these data indicate the role of CD25 in Treg development and function is mediating Foxp3 expression. However, the ability of the Foxp3⁺ T cells to act as suppressors is not dependent on expression of CD25. For instance, infection of CD4⁺/CD25⁻ T cells with a retrovirus expression *foxp3* gene converted those cells to a regulatory phenotype [1,24]. Therefore, induction of Foxp3 expression is necessary and sufficient for regulatory cell function but induction of CD25 expression is not absolutely required.

In summary, we demonstrated that recombinant Foxp3 protein with cell penetration capacity could enhance Treg cell function and of potentially therapeutic in arthritis with impaired Treg cell function.

Acknowledgments

Funding

This work was supported by a grant from NIH to CQC (AR055254) and Portland VA Medical Center to CQC.

References

1. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. *Science*. 2003; 299:1057–1061. [PubMed: 12522256]
2. Sakaguchi S, Powrie F. Emerging challenges in regulatory T cell function and biology. *Science*. 2007; 317:627–629. [PubMed: 17673654]
3. Wildin RS, Smyk-Pearson S, Filipovich AH. Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. *J Med Genet*. 2002; 39:537–545. [PubMed: 12161590]
4. Long SA, Buckner JH. CD4+FOXP3+ T regulatory cells in human autoimmunity: more than a numbers game. *J Immunol*. 2011; 187:2061–2066. [PubMed: 21856944]
5. Zhou X, Bailey-Bucktrout S, Jeker LT, Bluestone JA. Plasticity of CD4(+) FoxP3(+) T cells. *Curr Opin Immunol*. 2009; 21:281–285. [PubMed: 19500966]
6. Zhou X, Bailey-Bucktrout SL, Jeker LT, Penaranda C, Martinez-Llordella M, Ashby M, Nakayama M, Rosenthal W, Bluestone JA. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. *Nat Immunol*. 2009; 10:1000–1007. [PubMed: 19633673]
7. Bailey-Bucktrout SL, Bluestone JA. Regulatory T cells: stability revisited. *Trends Immunol*. 2011; 32:301–306. [PubMed: 21620768]
8. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. *Nat Immunol*. 2003; 4:330–336. [PubMed: 12612578]
9. Loser K, Hansen W, Apelt J, Balkow S, Buer J, Beissert S. In vitro-generated regulatory T cells induced by Foxp3-retrovirus infection control murine contact allergy and systemic autoimmunity. *Gene Ther*. 2005; 12:1294–1304. [PubMed: 15973443]
10. Zheng Q, Xu Y, Liu Y, Zhang B, Li X, Guo F, Zhao Y. Induction of Foxp3 demethylation increases regulatory CD4+CD25+ T cells and prevents the occurrence of diabetes in mice. *J Mol Med (Berl)*. 2009; 87:1191–1205. [PubMed: 19841877]
11. Choi JM, Shin JH, Sohn MH, Harding MJ, Park JH, Tobiasova Z, Kim DY, Maher SE, Chae WJ, Park SH, Lee CG, Lee SK, Bothwell AL. Cell-permeable Foxp3 protein alleviates autoimmune disease associated with inflammatory bowel disease and allergic airway inflammation. *Proc Natl Acad Sci U S A*. 2010; 107:18575–18580. [PubMed: 20937878]
12. Schwarze SR, Hruska KA, Dowdy SF. Protein transduction: unrestricted delivery into all cells? *Trends Cell Biol*. 2000; 10:290–295. [PubMed: 10856932]
13. Zhou H, Wu S, Joo JY, Zhu S, Han DW, Lin T, Trauger S, Bien G, Yao S, Zhu Y, Siuzdak G, Scholer HR, Duan L, Ding S. Generation of induced pluripotent stem cells using recombinant proteins. *Cell Stem Cell*. 2009; 4:381–384. [PubMed: 19398399]
14. Yomogida K, Chou Y, Pang J, Baravati B, Maniaci BJ, Wu S, Zhu Y, Chu CQ. Streptavidin suppresses T cell activation and inhibits IL-2 production and CD25 expression. *Cytokine*. 2012; 58:431–436. [PubMed: 22410319]
15. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. *J Immunol*. 1995; 155:1151–1164. [PubMed: 7636184]
16. Sakaguchi N, Takahashi T, Hata H, Nomura T, Tagami T, Yamazaki S, Sakihama T, Matsutani T, Negishi I, Nakatsuru S, Sakaguchi S. Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. *Nature*. 2003; 426:454–460. [PubMed: 14647385]
17. Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human immune system. *Nat Rev Immunol*. 2010; 10:490–500. [PubMed: 20559327]

18. Miyara M, Wing K, Sakaguchi S. Therapeutic approaches to allergy and autoimmunity based on FoxP3+ regulatory T-cell activation and expansion. *J Allergy Clin Immunol*. 2009; 123:749–755. quiz 756–747. [PubMed: 19348913]
19. Trzonkowski P, Bieniaszewska M, Juscinska J, Dobyszek A, Krzystyniak A, Marek N, Mysliwska J, Hellmann A. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127– T regulatory cells. *Clin Immunol*. 2009; 133:22–26. [PubMed: 19559653]
20. Allan SE, Alstad AN, Merindol N, Crellin NK, Amendola M, Bacchetta R, Naldini L, Roncarolo MG, Soudeyns H, Leving MK. Generation of potent and stable human CD4+ T regulatory cells by activation-independent expression of FOXP3. *Mol Ther*. 2008; 16:194–202. [PubMed: 17984976]
21. Cheng G, Yu A, Dee MJ, Malek TR. IL-2R Signaling Is Essential for Functional Maturation of Regulatory T Cells during Thymic Development. *Journal of Immunology*. 2013; 190:1567–1575.
22. Miyara M, Sakaguchi S. Human FoxP3(+)CD4(+) regulatory T cells: their knowns and unknowns. *Immunol Cell Biol*. 2011; 89:346–351. [PubMed: 21301480]
23. Cheng G, Yu A, Malek TR. T-cell tolerance and the multi-functional role of IL-2R signaling in T-regulatory cells. *Immunol Rev*. 2011; 241:63–76. [PubMed: 21488890]
24. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. *Immunity*. 2005; 22:329–341. [PubMed: 15780990]

- Polyarginine tagged Foxp3 protein can enter cells freely and enhance Treg function.
- Cell penetrating Foxp3 protein suppressed arthritis in an animal model.
- Exogenous Foxp3 is potentially therapeutic for arthritis and other autoimmune diseases.

A **B** **C**

Figure 1. Generation of cell-permeable Foxp3-11R

(A) A schematic presentation of the Foxp3 fusion protein. (B) SKG mouse splenocytes were incubated with 10 μ g/ml of Foxp3-11R, ASCL1-11R or culture medium in anti-CD3/CD28 coated plates for 120 hours, and Foxp3 was stained intracellularly. Mean fluorescence of Foxp3 was compared in the three treatment group. Data are representative of three independent experiments and mean $\pm$ SD (n=3). * p <0.05. (C) Splenocytes were treated as in (B) and stained with Annexin V and propidium iodide (PI). Figure shows CD4⁺ T cells stained by Annexin V (pooled data of three experiments, n=6 in each group).

Figure 2. Foxp3-11R treatment did not upregulate CD25, but induced Treg-like cells
 (A) SKG mouse splenocytes were incubated with 10 μ g/ml of Foxp3-11R, ASCL1-11R or culture medium in anti-CD3/CD28 coated plates for 120 hours, and CD25 on cell surface was stained. (B) Suppressor cells (sup) were prepared by incubating SKG mouse splenocytes with 40 μ g/ml of Foxp3-11R, ASCL1-11R, or culture medium for 1 hour and washed twice. As responder cells (res), SKG mouse splenocytes were stained with CFSE. Suppressor cells and responder cells were mixed at various ratios. Data are representative of three independent experiments.

Figure 3. Foxp3-11R prevented progression of arthritis in SKG mice

(A) Seven days after arthritis induction, SKG mice were treated with Foxp3-11R or ASCL1-11R for 7 days. Fourteen days after final treatment, splenocytes were harvested and Foxp3 was stained intracellularly. Data are CD4 T cell gated and mean $\pm$ SD (n=4). * p <0.05 (B) Severity of arthritis was monitored daily after the above treatment (n=10 in each group). (p=0.78 at week 4, p=0.02 at week 6 and p=0.033 at week 8, pooled data of two experiments).